IMA ImageneBio, Inc. Insider Trading

Director SLATTERY JOSEPH P purchased 16,000 shares of IMA at $5.99 (12/24); stock at -64.2% from 52-week high, -21.4% over 90 days.

SLATTERY JOSEPH P, a Director, acquired 16,000 shares at $5.99 on 2025-12-24, his first open-market purchase of IMA. The purchase occurred after the stock declined -21.4% over the prior 90 days and now sits -64.2% below its 52-week high of $17.90. The company is unprofitable with a net income of $-24,779,000 and zero revenue in the latest quarter, alongside annual revenue contraction of -41.4%, indicating a distressed operating backdrop. Across his cross-ticker track record, SLATTERY has executed 4 prior buys averaging +80.2% returns over 90 days with a 100% win rate; however, those results are not ticker-specific and do not establish predictive relevance to IMA's current distress. The director's entry at a multi-year depressed level warrants observation of whether this signals board confidence in recovery or is merely opportunistic accumulation in a deeply challenged business.

Director Stampacchia Otello bought 267,556 shares of IMA at $29.90 ($8.0M) on 2025-07-25, raising stake to 454,982 shares (+142.8%).

Stampacchia Otello, a director, executed a large open-market purchase of 267,556 shares for $7,999,924.40, increasing his stake by 142.8% from 187,426 to 454,982 shares. The transaction occurred at $29.90 per share, a significant premium to the current price of $15.29 (just 5 trading days later), representing a near 49% decline in valuation. This is noteworthy given the company's recent listing status (3 trading days old as of transaction), unprofitable status with full-year net income of $-2,767,000.00, and sharply contracting revenues (-41.4% annual growth with latest quarterly revenue of $1,185,000.00). The director's substantial capital commitment to a newly listed, revenue-declining, unprofitable company at a price now well above current trading levels warrants investor scrutiny of the transaction's circumstances, post-IPO trading volatility, and forward guidance.

Director Bonita David P purchases 83,611 shares of IMA for $2.5M just 3 days after IPO at $29.90

Director Bonita David P acquired 83,611 shares (83.6K shares) for $2,499,968.90 ($2.5M) on 2025-07-25, three days after ImageneBio's recent listing, growing her post-transaction holdings to 287,885 shares (287.9K shares) from 204,274 shares (204.3K shares), a 40.9% increase in position size. The company has negative fundamentals: net income of $-2,767,000.00 ($-2.8M) in the latest quarter, annual revenue decline of -41.4%, and unprofitability over its most recent full fiscal year. This substantial open-market purchase by a director in the immediate post-IPO window, despite deteriorating operational performance (declining revenue, ongoing losses), presents a material signal requiring investor scrutiny of the company's forward guidance and the director's conviction rationale, particularly given the $737.9M market cap and the apparent contrast between her equity commitment and the negative financial trajectory.